Hansa Biopharma — Board/Management Information 2017

Mar 31, 2017

• PRESS RELEASE - March 31, 2017

Hansa Medical appoints Sam Agus as new Chief Medical Officer

Hansa Medical AB (publ), a biopharmaceutical company developing novel immunomodulatory enzymes, announced today the recruitment of Sam Agus, MD, as Chief Medical Officer.

Sam Agus has a broad experience from the pharmaceutical industry and was most recently Chief Specialist, Medical Affairs Neurology at H. Lundbeck A/S. He has previously held various leading positions at several pharmaceutical companies, including Shire, Solvay Pharmaceuticals and Abbott Laboratories.

He is a board-certified neurologist and has extensive experience in medical strategy, multidisciplinary team leadership, medical marketing as well as clinical trial design and product launches. His therapy area expertise includes neurology, psychiatry, gastroenterology, women's health and rare diseases.

Sam's key focus will be on the company's lead project IdeS. IdeS is now in late stage clinical development focused on kidney transplantation in sensitized patients. He will plan and implement activities to build an effective organisation that will support the overall company strategy around the global market preparations for the launch of IdeS.

"We are very pleased to have Sam joining our team in this truly exciting phase for Hansa Medical. His experience from building and leading strong teams will be a central part in our next phase towards commercialization of IdeS", said Göran Arvidson, President and CEO of Hansa Medical. "I also want to thank Steven Glazer for his contribution to the development of IdeS and Hansa Medical. Steven will continue to provide strategic advice to Hansa Medical."

About Hansa Medical AB

Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for autoimmune diseases and transplantation. The lead project IdeS is a proprietary antibody-degrading enzyme in late-stage clinical development for kidney transplant patients. The company's portfolio also includes HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already on the market. The company is based in Lund, Sweden. Hansa Medical's share (ticker: HMED) is listed on Nasdaq Stockholm.

This information is information that Hansa Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 08:00 CET on March 31, 2017.

For further information, please contact: Hansa Medical AB (Publ) Göran Arvidson, President and CEO Mobile: +46 706 33 30 42 E-mail: goran.arvidson@hansamedical.com www.hansamedical.com